Evidence map›Paper›PMID 41830752›Full record

ArticleBreast (Edinburgh, Scotland)2026

Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer.

Adam Brufsky, Rachel M Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B Cohen, Melissa Estevez, Paul Cottu, Giuseppe Curigliano, Hope S Rugo

Erratum issued Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06495164 (Palbociclib Treatment Patterns and Outcomes in HR+/HER2- MBC), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06495164 active not recruitingnot on this map

Palbociclib Treatment Patterns and Outcomes in HR+/HER2- MBC: Flatiron Database Analysis

TypeobservationalSponsorPfizerRan2024 to 2026Enrolled1ConditionsBreast Cancer, Malignant Neoplasm of BreastArmsPalbociclib, Aromatase inhibitor, Ribociclib, Abemaciclib
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Adam BrufskyDivision of Hematology/Oncology, Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: brufskyam@upmc.edu.
Rachel M LaymanDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xianchen LiuUS Oncology Medical Affairs, Pfizer Inc, New York, NY, USA.
Benjamin LiGlobal Biometrics & Data Management, Pfizer Inc, New York, NY, USA.
Lynn McRoyUS Oncology Medical Affairs, Pfizer Inc, New York, NY, USA.
Aaron B CohenFlatiron Health Inc., New York, NY, USA.
Melissa EstevezFlatiron Health Inc., New York, NY, USA.
Paul CottuDepartment of Medical Oncology & Institute of Women Cancers, Institut Curie, Université Paris Cité, Paris, France.
Giuseppe CuriglianoDepartment of Oncology and Hemato-Oncology, University of Milano, Milano, Italy; European Institute of Oncology (IEO) IRCCS, Milano, Italy.
Hope S RugoBreast Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCyclin-dependent kinase (CDK) 4/6 inhibitors plus endocrine therapy (ET) are more effective than ET alone in diverse populations of patients with HR+/HER2- metastatic breast cancer (MBC). However, real-world effectiveness data for CDK4/6 inhibitors plus ET combination in bone-only MBC are limited.

methodsThis retrospective, real-world study compared clinical outcomes of first-line (1L) palbociclib (PAL) plus an aromatase inhibitor (AI) with AI alone in bone-only MBC using data from the US-based, nationwide Flatiron Health Research database. Eligible patients had HR+/HER2- bone-only MBC, were ≥18 years of age, and started 1L PAL + AI or AI alone from February 2015 to June 2022. Stabilized inverse probability of treatment weighting (sIPTW) was used to balance baseline characteristics. Overall survival (OS), real-world progression-free survival (rwPFS), and time to chemotherapy (TTC) were evaluated.

resultsOf 974 eligible patients with bone-only MBC, 538 received PAL + AI and 436 received AI alone. After sIPTW, baseline patient characteristics were balanced between treatment groups. Median follow-up was 31.9 months for the PAL + AI group and 35.8 months for the AI group. After sIPTW, the PAL + AI group compared with the AI group had a significantly longer OS (median 63.4 vs 51.3 months; HR = 0.78; 95% CI, 0.64-0.97, P = 0.0221), rwPFS (median 23.0 vs 18.2 months; HR = 0.72; 95% CI, 0.59-0.87, P = 0.0008), and TTC (median 47.9 vs 40.6 months; HR = 0.79; 95% CI, 0.66-0.96, P = 0.016). Consistent results were observed in unadjusted and sensitivity analyses.

conclusionThis real-world study demonstrates that first-line PAL + AI versus AI alone was associated with prolonged OS, rwPFS, and TTC in patients with HR+/HER2- bone-only MBC. TRIAL REGISTRATION NUMBER: NCT06495164.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBone NeoplasmsBreast NeoplasmsPiperazinesPyridinesAdultAgedErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedProgression-Free SurvivalReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesAromatase InhibitorsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespalbociclibPiperazinesPyridinesReceptors, EstrogenReceptors, ProgesteroneBone metastasisCyclin-dependent kinasesHR+/HER2−Metastatic breast cancerPalbociclibReal-world

Identifiers

PMID41830752
PMCPMC12996934

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.